|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.00 TWD | +0.76% |
|
+1.52% | -3.85% |
| Capitalization | 31.06B 991M 835M 761M 726M 1.35B 89.88B 1.4B 8.84B 3.52B 43.24B 3.71B 3.64B 152B | P/E ratio 2023 |
-29.5x | P/E ratio 2024 | -28.2x |
|---|---|---|---|---|---|
| Enterprise value | 35.54B 1.13B 955M 871M 830M 1.54B 103B 1.6B 10.12B 4.02B 49.47B 4.25B 4.16B 174B | EV / Sales 2023 |
23.5x | EV / Sales 2024 | 22.3x |
| Free-Float |
76.01% | Yield 2023 |
3.39% | Yield 2024 | 1.71% |
| 1 day | +0.76% | ||
| 1 week | +1.52% | ||
| Current month | -0.74% | ||
| 1 month | -4.31% | ||
| 3 months | +6.24% | ||
| 6 months | +11.78% | ||
| Current year | -3.85% |
| 1 week | 39.3 | 40.5 | |
| 1 month | 38.35 | 44.3 | |
| Current year | 38.35 | 44.55 | |
| 1 year | 29.12 | 44.55 | |
| 3 years | 29.12 | 58.79 | |
| 5 years | 29.12 | 58.79 | |
| 10 years | 20.99 | 64.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jui Pao Hsu
CEO | Chief Executive Officer | - | 02/08/1998 |
An Ni Mao
DFI | Director of Finance/CFO | - | 07/12/2022 |
Pei Chen Tsai
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/1983 |
| Director | Title | Age | Since |
|---|---|---|---|
Su Chi Wang
CHM | Chairman | - | 29/11/2022 |
Shih Chun Ho
BRD | Director/Board Member | 61 | 13/06/2010 |
Po Chih Chang
BRD | Director/Board Member | - | 13/06/2010 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.76% | +1.52% | +2.38% | -2.95% | 951M | ||
| +0.17% | -1.72% | +23.18% | +210.44% | 929B | ||
| -0.45% | +1.44% | +55.91% | +52.76% | 587B | ||
| +1.76% | +3.61% | +20.03% | +53.25% | 409B | ||
| +0.39% | +1.40% | +22.72% | +30.42% | 374B | ||
| +0.28% | +7.49% | +29.48% | +31.05% | 320B | ||
| +1.05% | +5.42% | +32.60% | +56.70% | 311B | ||
| +1.82% | -0.43% | +46.26% | +12.75% | 301B | ||
| -0.95% | +4.11% | -44.82% | -37.79% | 219B | ||
| +0.82% | -3.94% | +26.80% | +53.79% | 199B | ||
| Average | +0.57% | +1.76% | +21.45% | +46.04% | 364.97B | |
| Weighted average by Cap. | +0.46% | +1.36% | +27.41% | +80.40% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 1.39B 44.46M 37.47M 34.16M 32.58M 60.53M 4.03B 62.88M 397M 158M 1.94B 167M 163M 6.83B | 1.62B 51.6M 43.49M 39.64M 37.81M 70.26M 4.68B 72.98M 461M 183M 2.25B 194M 190M 7.92B |
| Net income | -995M -31.75M -26.75M -24.39M -23.26M -43.23M -2.88B -44.9M -283M -113M -1.39B -119M -117M -4.87B | -1.1B -35.2M -29.66M -27.04M -25.79M -47.93M -3.19B -49.79M -314M -125M -1.54B -132M -129M -5.4B |
| Net Debt | 2.2B 70.09M 59.06M 53.84M 51.35M 95.42M 6.36B 99.12M 626M 249M 3.06B 263M 257M 10.76B | 4.48B 143M 120M 110M 105M 195M 12.97B 202M 1.28B 507M 6.24B 536M 525M 21.93B |
Employees
-
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/02/26 | 40.00 NT$ | +0.76% | 1,106,263 |
| 10/02/26 | 39.70 NT$ | +1.66% | 1,209,292 |
- Stock Market
- Equities
- 4123 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















